RT Book, Section
A1 Duncan, Jacque L.
A1 Parikh, Neeti B.
A1 Seitzman, Gerami D.
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1193145050
T1 Adverse Ocular Effects of Systemic Drugs
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193145050
RD 2024/04/23
AB Systemically  administered  drugs  produce  a  wide  variety  of  adverse  effects  on  the  visual  system.  Table  7–3  lists  the  major  examples.  The  likelihood  of  most  complications  is  rare,  but  if  visual  changes  develop  while  a  patient  is  being  treated  with  these  medications,  the  patient  should  be  referred  to  an  eye  care  professional  for  an  eye  examination.  Screening  for  toxic  retinopathy  is  recommended  at  baseline  in  patients  receiving  long-term  chloroquine  or  hydroxychloroquine  therapy.  Screening  should  occur  with  automated  perimetry  and  optical  coherence  tomography  macular  scans  once  at  baseline.  If  no  baseline  abnormalities  are  present,  screening  should  be  repeated  annually  beginning  after  5  years.  More  frequent  screening  is  necessary  in  patients  treated  with  doses  greater  than  5.0  mg/kg  real  weight/day  of  hydroxychloroquine  or  greater  than  2.3  mg/kg/day  of  chloroquine,  in  patients  with  kidney  disease  or  in  those  taking  tamoxifen.